Perrigo Past Earnings Performance

Past criteria checks 0/6

Perrigo's earnings have been declining at an average annual rate of -47.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 1.2% per year.

Key information

-47.6%

Earnings growth rate

-47.3%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate1.2%
Return on equity-3.2%
Net Margin-3.3%
Last Earnings Update28 Sep 2024

Recent past performance updates

Recent updates

Is Perrigo (NYSE:PRGO) A Risky Investment?

Dec 06
Is Perrigo (NYSE:PRGO) A Risky Investment?

Perrigo Company: Great Combination Of Future Growth With A Low Valuation

Nov 19

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Nov 07
Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Oct 18
Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276

Aug 21
Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276

The Play On Perrigo

Aug 16

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Aug 07
Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Jul 03
Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

May 29
These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Mar 27
Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Feb 01
These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Dec 28
The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Nov 15

The Prognosis For Perrigo

Aug 30

Perrigo Outlook Healed By Repositioning

Jun 12

Perrigo raises dividend by 5% to $0.273/share

Feb 21

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Jan 18

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Nov 08

Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant

Nov 01

Perrigo Company plc Is Back On Track

Oct 20

Perrigo to face FDA AdCom meeting for OTC contraceptive

Sep 12

Perrigo responds to 'misleading and inaccurate information' on Zantac claims

Aug 17

Perrigo reports Q2 mixed results; raises FY22 organic net sales growth outlook

Aug 09

Perrigo declares $0.26 dividend

Aug 02

Perrigo: HRA Acquisition To Drive Significant Growth

Jul 20

Perrigo unit seeks FDA over-the-counter approval for birth control pill Opill

Jul 11

Revenue & Expenses Breakdown

How Perrigo makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:PRGO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
28 Sep 244,392-1471,182114
29 Jun 244,428-1141,215118
30 Mar 244,55611,246120
31 Dec 234,656-41,272123
30 Sep 234,654111,227126
01 Jul 234,630-571,204126
01 Apr 234,559-1311,210125
31 Dec 224,452-1311,161123
01 Oct 224,401-861,168121
02 Jul 224,344-881,170119
02 Apr 224,203-1351,107120
31 Dec 214,139-1311,108122
02 Oct 214,087-2151,146125
03 Jul 214,047-1351,126128
03 Apr 214,015-111,105125
31 Dec 204,088441,100122
26 Sep 204,358771,096148
27 Jun 204,5461431,109162
28 Mar 204,7461401,147175
31 Dec 193,8701591,095119
28 Sep 194,7102471,157173
29 Jun 194,652871,142172
30 Mar 194,6891141,127220
31 Dec 184,7321311,124219
29 Sep 184,8201231,133221
30 Jun 184,9182351,158216
31 Mar 184,9691291,158166
31 Dec 174,9461201,146168
30 Sep 174,994-1,3131,161162
01 Jul 175,025-2,9471,154174
01 Apr 175,127-3,4121,177179
31 Dec 165,281-4,0131,206184
01 Oct 165,308-2,8721,241189
02 Jul 165,320-1,0211,289180
02 Apr 165,395-5091,313196
31 Dec 155,015-21,144186
26 Sep 154,997144912193
27 Jun 154,227136742188
28 Mar 154,217203591163
27 Dec 144,172347487173
27 Sep 144,079190570157
28 Jun 143,914233566153
29 Mar 143,884192528146
28 Dec 133,800256616129

Quality Earnings: PRGO is currently unprofitable.

Growing Profit Margin: PRGO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRGO is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.

Accelerating Growth: Unable to compare PRGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRGO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: PRGO has a negative Return on Equity (-3.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 21:27
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/28
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Perrigo Company plc is covered by 38 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Ishan MajumdarBaptista Research
Douglas TsaoBarclays